24C
Delhi
Saturday, February 27, 2021

Covaxin consent form says vax administered without ph-3 trial

- Advertisement -

‘Covaxin likely to be available for public use by Feb’New Delhi, Jan 16 (IANS) Amid the vaccinaton drive against Covid-19, it has emerged that there is a separate consent form for those who are administered the ‘Covaxin’ vaccine manufactured by Bharat Biotech.

The form says that “In phase-1 and phase-2 clinical trial ‘Covaxin’ has demonstrated the ability to produce antibodies against Covid-19, however the clinical efficacy of Covaxin is yet to be established and it is still being studied in phase-3 clinical trial, hence it is important to appreciate that receiving the vaccine does not mean that the other precautions related to Covid-19 should not be followed.”

The form says that in case of any adverse and serious condition, the receiver will be provided utmost care at the health centre and in case of casuality the compensation will be provided by Bharat Biotech.

“The compensation for serious adverse event will be paid by sponsor BBIL if the SAE is proven to be casually related to the vaccine,” it said.

READ ALSO:  India should aim to become world's largest coal exporter: PM

Serious concerns were raised in certain quarters including by opposition parties and Congress leader Manish Tewari has questioned the efficacy of ‘Covaxin’ while the Prime Minister has warned people not to believe in “rumours”.

The world’s biggest vaccination drive come almost a year after the first coronavirus case was detected in India, and since then the deadly virus has claimed over 1.5 lakh lives and infected one crore people. The first case came to the fore on January 30, 2020 in Kerala.

READ ALSO:  50% chance Oxford Covid-19 vaccine trial will yield ''no result''

Two vaccines — the Oxford vaccine ‘Covishield’ manufactured by the Serum Institute of India, and indigenously developed ‘Covaxin’ by Bharat Biotech — will be administered to priority groups. So far, the central government has procured 1.1 crore Covishield and 55 lakh Covaxin vaccines at a cost of Rs 200 and Rs 206 per dose, respectively.

READ ALSO:  Oxford scientists prepare to expand trials of potential COVID-19 vaccine

In Delhi, which has 81 vaccination sites, ‘Covaxin’ has been allotted to six Centre-run hospitals while 75 Delhi government and private hospitals will receive ‘Covishield’.

The vaccine is first offered to the healthcare workers, frontline workers and those above 50 years of age, followed by the below-50 population with comorbidities, and finally to the remaining population based on disease epidemiology and vaccine availability.

Source: IANS

India Updates
India Updates is an independent news & Information website. Follow us for regular updates on News and Information.

Follow Us On

Related News

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Trending Topics In India

Covid 19 India Updates

Trending News In India

Trending Showbiz

Trending Sports

Latest Trending News In India

Panic Bond: Equities crash on global sell-off, high yields

Mumbai, Feb 26 (IANS): Sell-offs in global bond markets sparked panic in India's benchmark equity indices which declined the most since May 2020 on Friday. Investors...

Bharat Biotech to supply 20 million doses of Covaxin to Brazil

Hyderabad, Feb 26 (IANS) Bharat Biotech International Ltd on Friday confirmed that it has signed an agreement with Brazil for supply of 20 million...

Everyone must come together for climate: Bill Gates

New Delhi, Feb 26 (IANS) Technologist and philanthropist Bill Gates, talking about the perils of climate change in a conversation with Alok Sharma, President...

India’s eight core industries’ production remains flat in Jan

New Delhi, Feb 26 (IANS) The production of India's eight major industries remained flat on a year-on-year basis during January 2021. The Index of Eight...